Nonpeptide glycoprotein IIB/IIIA inhibitors. 19. A new design paradigm employing linearly minimized, centrally constrained, exosite inhibitors

Bioorg Med Chem Lett. 1999 Mar 22;9(6):863-8. doi: 10.1016/s0960-894x(99)00104-3.

Abstract

A new series of potent, linearly-minimized, orally active, selective GPIIb/IIIa inhibitors is identified. Thus 15 (L-750,034) achieves interaction via a constrained, non-turned conformation that maintains the proper distance between its charged termini and full sulfonamide exosite interaction. The diminutive stature and the proposed linear conformation of L-750,034 define a new paradigm for the conceptualization of RGD mimics.

MeSH terms

  • Benzamides / pharmacology*
  • Drug Design
  • Inhibitory Concentration 50
  • Models, Chemical
  • Models, Molecular
  • Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*
  • Time Factors

Substances

  • Benzamides
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • 4-hydroxybenzamide